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ORIGINAL ARTICLE
The glucagon-like peptide-1 receptor as a potential treatment
target in alcohol use disorder: evidence from human genetic
association studies and a mouse model of alcohol dependence
P Suchankova1,2, J Yan3,4, ML Schwandt5, BL Stangl3, EC Caparelli6, R Momenan7, E Jerlhag2, JA Engel2, CA Hodgkinson8, M Egli9,
MF Lopez10, HC Becker10,11,12, D Goldman8, M Heilig5, VA Ramchandani3 and L Leggio1,6,13
The hormone glucagon-like peptide-1 (GLP-1) regulates appetite and food intake. GLP-1 receptor (GLP-1R) activation also
attenuates the reinforcing properties of alcohol in rodents. The present translational study is based on four human genetic
association studies and one preclinical study providing data that support the hypothesis that GLP-1R may have a role in the
pathophysiology of alcohol use disorder (AUD). Case–control analysis (N= 908) was performed on a sample of individuals enrolled
in the National Institute on Alcohol Abuse and Alcoholism (NIAAA) intramural research program. The Study of Addiction: Genetics
and Environment (SAGE) sample (N= 3803) was used for conﬁrmation purposes. Post hoc analyses were carried out on data from a
human laboratory study of intravenous alcohol self-administration (IV-ASA; N= 81) in social drinkers and from a functional magnetic
resonance imaging study in alcohol-dependent individuals (N= 22) subjected to a Monetary Incentive Delay task. In the preclinical
study, a GLP-1R agonist was evaluated in a mouse model of alcohol dependence to demonstrate the role of GLP-1R for alcohol
consumption. The previously reported functional allele 168Ser (rs6923761) was nominally associated with AUD (P= 0.004) in the
NIAAA sample, which was partially replicated in males of the SAGE sample (P= 0.033). The 168Ser/Ser genotype was further
associated with increased alcohol administration and breath alcohol measures in the IV-ASA experiment and with higher BOLD
response in the right globus pallidus when receiving notiﬁcation of outcome for high monetary reward. Finally, GLP-1R agonism
signiﬁcantly reduced alcohol consumption in a mouse model of alcohol dependence. These convergent ﬁndings suggest that the
GLP-1R may be an attractive target for personalized pharmacotherapy treatment of AUD.
Translational Psychiatry (2015) 5, e583; doi:10.1038/tp.2015.68; published online 16 June 2015
INTRODUCTION
Glucagon-like peptide-1 (GLP-1), signaling via its receptor
(GLP-1R), has an important role in the gut–liver–brain axis. In
addition to its role as a gut-derived incretin, GLP-1 acts as a
neuropeptide, as it is produced by preproglucagon neurons in the
nucleus of the solitary tract.1 Clinical studies show that GLP-1R is
involved in food-related reward processing by acting as a meal
termination signal.2 GLP-1R mRNA and protein are widely
expressed in the human and rat brain.3,4 In fact, the receptor
gene is expressed in mesolimbic areas involved with reward
processing in both species, including the globus pallidus, ventral
tegmental area and nucleus accumbens.3,4 The latter areas are
innervated directly by GLP-1-producing neurons projecting from
the nucleus of the solitary tract5 providing a route by which GLP-1
may affect motivation-related mechanisms.
The GLP-1R agonist, exendin-4, was recently shown to attenuate
the reinforcing properties of alcohol in rodents,6,7 by preventing
alcohol-induced accumbal dopamine release.6 Conversely, the
GLP-1R antagonist, exendin-9-39, increased alcohol intake in rats.7
These studies suggest a role of GLP-1R in alcohol use disorder
(AUD), which represents the main hypothesis underlying this study.
Although preclinical research to date has suggested a potential
role of GLP-1R in AUD, there is no human evidence to support this.
Given that AUD is partially heritable, with contributions from
numerous, yet to be established, loci,8 studying genetic variation
of a pathway of interest, like GLP-1R in our case, is a possible
1Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health, Bethesda, MD, USA; 2Department of Pharmacology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
3Section on Human Psychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health,
Bethesda, MD, USA; 4Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA; 5Laboratory of
Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA; 6Intramural Research Program, National
Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; 7Section on Brain Electrophysiology and Imaging, Laboratory of Clinical and Translational Studies,
National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA; 8Laboratory of Neurogenetics, National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health, Bethesda, MD, USA; 9Division of Neuroscience and Behavior, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA;
10Charleston Alcohol Research Center, Department of Psychiatry and Behavioral Science, Medical University of South Carolina, Charleston, SC, USA; 11Department of
Neurosciences, Medical University of South Carolina, Charleston, SC, USA; 12Ralph H Johnson VA Medical Center, Charleston, SC, USA and 13Center for Alcohol and Addiction
Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA. Correspondence: Dr L Leggio, Section on Clinical Psychoneuroendocrinology and
Neuropsychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National
Institutes of Health; 10 Center Drive (10CRC/15330) MSC 1108, Room 1-5429, Bethesda, MD 20892-1108, USA.
E-mail: lorenzo.leggio@nih.gov
Received 8 February 2015; revised 18 March 2015; accepted 6 April 2015
Citation: Transl Psychiatry (2015) 5, e583; doi:10.1038/tp.2015.68
www.nature.com/tp
approach. Speciﬁcally, we present ﬁve complementary studies,
that is, four human genetic association studies investigating the
genetics of GLP-1R in the context of AUD, and one preclinical
study examining the role of GLP-1R agonism in a mouse model of
alcohol dependence. First, we tested whether genetic variation in
GLP1R is associated with AUD in participants enrolled at the
National Institute on Alcohol Abuse and Alcoholism Laboratory of
Clinical and Translational Studies (LCTS). Signiﬁcant associations
were further investigated for conﬁrmatory purposes in the Study
of Addiction: Genetics and Environment (SAGE) genome-wide
association study sample. Post hoc analyses were conducted from
a human laboratory study to explore the effects of identiﬁed
GLP1R risk alleles on intravenous alcohol self-administration
(IV-ASA), to provide initial functional validation of our hypothesis.
As genetic variations are associated with changes in brain
activity,9 further post hoc analyses were made using functional
magnetic resonance imaging (fMRI) data to explore the effect of
GLP1R risk alleles in alcohol-dependent individuals. Finally, the
preclinical study investigated GLP-1R agonism on alcohol con-
sumption as a pharmacological validation of the role of GLP-1R in
alcohol dependence.
MATERIALS AND METHODS
Study procedure
LCTS study (Study 1). Participants in the LCTS study were a subset
(N= 908) of a larger sample (N=1068) recruited at the National Institutes of
Health (NIH) Clinical Center in Bethesda, MD, USA under two NIH
Institutional Review Board-approved screening and evaluation protocols.
Participants provided written informed consent. Cases comprised indivi-
duals that had either past and/or current AUD (N= 669), while controls had
no past or current alcohol and/or substance use disorder (N=239). AUD
was diagnosed based on criteria for alcohol abuse and dependence using
the SCID (Structured Clinical Interview for DSM-IV-TR Axis I Disorders).10
Lifetime psychotic disorders, but not other psychiatric comorbidity, were
exclusionary. To avoid potential confounds from population stratiﬁcation,
the analysis was limited to the two major self-reported ancestries included
in the sample, that is, Caucasian and African American (Table 1), thus
excluding subjects of mixed, Asian or unknown descent (N= 104). Control
subjects that had a past or current substance use disorder (other than
nicotine) were also excluded (N=11), as were subjects with missing SCID
data (N= 50).
SAGE study (Study 2). For conﬁrmation, we used the SAGE genome-wide
association study, whose sample of alcohol-dependent and nondependent
control individuals has been described in detail previously.11,12 SAGE is a
dbGaP study (accessions phs000092.v1.p1.c1 and c2), part of the Gene
Environment Association Studies consortium. The sample was selected
from the Collaborative Study on the Genetics of Alcoholism, the Family
Study of Cocaine Dependence and the Collaborative Genetic Study of
Nicotine Dependence data sets.
A lifetime history of alcohol dependence was diagnosed using DSM-IV
criteria. Some control subjects met criteria for nicotine dependence on the
basis of the Fagerström Test for Nicotine Dependence, but none had
alcohol or any other substance dependence. Controls who endorsed ⩾ 3
DSM-IV symptoms of alcohol dependence, but did not cluster within a
12-month period, were removed as they may still have an increased
genetic risk (N= 55).12 GLP1R single-nucleotide polymorphisms (SNPs) were
extracted using PLINK (version 1.07).13 Duplicate cases were removed, as
were related subjects before analysis was initiated. The sample character-
istics of the combined sample of alcohol-dependent cases (N=1917) and
controls (N= 1886) are seen in Table 2. The Institutional Review Boards at
all participating sites approved data collection.
IV-ASA study (Study 3). Male and female 21–44-year-old nondependent
drinkers (N=81) were recruited for an NIH Institutional Review Board-
approved human laboratory study with the IV-ASA paradigm (Table 3).
Participants provided written informed consent.
The IV-ASA method, in which participants self-administer IV alcohol
upon pressing a button, has the advantage over oral alcohol exposure to
provide precision in terms of breath alcohol concentration (BrAC)
exposure, and by assessing self-administration behavior driven primarily
by the pharmacological effects of alcohol.14 The IV-ASA experiment
consisted of two phases (details in Stangl et al.15). During the priming
phase (25 min), participants were prompted to push the button to receive
four small standardized alcohol infusions resulting in a BrAC level of
~ 30mg% at 10min for all participants. During the ad libitum phase (‘open-
bar’), the participants were free to press the button any time they wished
to receive the standardized IV alcohol infusion. The infusion rates were
determined using the subject’s age, height, weight and gender in a
physiologically based pharmacokinetic model,16 and implemented using
the Computerized Alcohol Infusion System.17 Each button press resulted in
a 7.5 mg% increase in BrAC at a ﬁxed rate of 3 mg% per minute for a ﬁxed
Table 1. Sample characteristics for the LCTS study
AUD Controls
Total sample Women Men Total sample Women Men
N (%) 670 (100) 199 (29.7) 471 (70.3) 238 (100) 99 (41.6) 139 (58.4)
Age (s.d.) 41.2 (±10.7) 41.9 (±10.8) 40.9 (±10.6) 30.9 (±10.1) 31.4 (±9.8) 30.6 (±10.3)
Self-reported ancestry
Caucasian 421 (62.8) 132 (66.3) 289 (61.4) 184 (77.3) 78 (78.8) 106 (76.3)
African American 249 (37.2) 67 (33.7) 182 (38.6) 54 (22.7) 21 (21.2) 33 (23.7)
Self-reported ethnicity
Hispanics 9 (1.3) 4 (2.0) 5 (1.1) 6 (2.5) 3 (3.0) 3 (2.2)
Smokers 363 (54.2) 104 (52.3) 259 (55.0) 18 (7.6) 6 (6.1) 12 (8.6)
Current alcohol dependence 578 (86.3) 175 (87.9) 403 (85.6) 0 0 0
Past alcohol dependence 169 (25.2) 53 (26.6) 117 (24.8) 0 0 0
Current alcohol abuse 21 (3.1) 4 (2.0) 17 (3.6) 0 0 0
Past alcohol abuse 43 (6.4) 11 (5.5) 32 (6.8) 0 0 0
Lifetime psychiatric comorbiditya
Mood disorder 131 (19.6) 60 (30.2) 71 (15.1) 10 (4.2) 4 (4.1) 6 (4.3)
Anxiety disorder 245 (36.6) 101 (50.8) 144 (30.6) 9 (3.8) 5 (5.2) 4 (2.9)
Substance use disorderb 435 (64.9) 114 (57.3) 321 (68.2) 0 0 0
Eating disorder 16 (2.4) 14 (7.0) 2 (0.4) 0 0 0
Abbreviations: AUD, alcohol use disorder; LCTS, Laboratory of Clinical and Translational Studies. aComplete Structured Clinical Interview for DSM-IV-TR Axis I
Disorders (SCID) available for 665 cases and 234 controls. bNot including alcohol use disorder. Data are presented as N (%) unless otherwise speciﬁed.
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duration of 2.5 min followed by a 1mg% decrease per minute until the
next button press. The button was inactivated (with the participant’s
knowledge) if the next push passed the pre-set upper limit for BrAC
exposure (100mg%). An Alcotest 7410 handheld breathalyzer (Draeger
Safety Diagnostics, Irving, TX, USA) was administered approximately every
15min during the session.
fMRI study (Study 4). Alcohol-dependent patients (N= 22) from an
Institutional Review Board-approved study18 were included in this analysis.
Participants provided written informed consent. Participants were
inpatients undergoing treatment for alcohol dependence at the NIH
Clinical Center. They were scanned at least 1 week, but not more than
4 weeks after alcohol abstinence;18 fMRI was performed using a modiﬁed
version of the Monetary Incentive Delay task.18
All the images were acquired in a 3 T MRI scanner (General Electric,
Milwaukee, WI, USA); for the anatomical, a T1-weighted sequence was used
(TE = 2.5 ms, TR = 6ms, 0.94 × 0.94× 1.2 mm3), and for the fMRI, a EPI-GRE
single-shot sequence was used with the following parameters: TE = 19.9
ms, TR = 1 s, 16 contiguous sagittal slices centering on the intrahemi-
spheric ﬁssure, ﬂip angle = 90 °, average 3.75 × 3.75mm2 in plane
resolution, slice thickness = 4mm, 1 mm gap, for a total of 500 (volumes)
seconds.
A total of 54 trials were randomly presented across three scanning runs.
Each trial was composed of four events: (1) anticipatory cue (three levels:
$0 (represented by a triangle), $1 (circle with one middle line) and $10
(circle with three lines)); (2) target (white square) for active response; (3)
notiﬁcation displaying the word ‘hit’ (successful trial is indicated) or the
world ‘win’ (successful trial is indicated and rewarded); and (4) feedback on
the trial outcome (amount earned in the trial and total earned until the
present moment in the study). Participants were instructed to respond on
a button box during the presentation of the target event. Stimuli were
projected on a screen at the foot of the scanner bed and viewed using a
head coil mirror. For additional details, see Bjork et al.18
Genotyping analyses (Studies 1–4). Genotyping for Studies 1, 3 and 4 was
performed at the National Institute on Alcohol Abuse and Alcoholism
Laboratory of Neurogenetics. Genomic DNA was extracted from whole
blood using standard protocols. DNA samples were genotyped using the
Illumina OmniExpress BeadChip array (Illumina, San Diego, CA, USA)
including more than 700 000 SNPs. The average genotype reproducibility
was 0.99994. GLP1R SNPs, locations spanning from the 5′ to the 3′ ﬂanking
regions, were selected from the Illumina data set for analysis. The LCTS
sample was split according to self-reported ancestry and deviation from
Hardy–Weinberg Equilibrium was assessed only in control subjects for all
40 SNPs located in GLP1R. SNPs with a Hardy–Weinberg Equilibrium P-
value o0.01 and a minor allele frequency of ⩽ 5% in Caucasian and/or
African Americans were excluded from the analysis. We also excluded
rs10305518 as this SNP was in perfect linkage disequilibrium (r2 = 1) with
rs10305514 leaving a total of 26 SNPs (Supplementary Table S1). For Study
2, samples were genotyped on the Illumina Human 1 M Beadchip by the
Center for Inherited Disease Research at Johns Hopkins University.11
GLP-1R agonist in a mouse model of alcohol dependence (Study 5). The
effects of AC3174, a GLP-1R agonist, on voluntary alcohol consumption
were evaluated in a mouse model of alcohol dependence. Adult male
C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME,
USA), individually housed and maintained in an AAALAC-approved facility
under a modiﬁed 12-h light–dark cycle (lights on at 0200 h). Food and
water were continuously available throughout the study. The study was
conducted at the Medical University of South Carolina, approved by the
Medical University of South Carolina Institutional Animal Care and Use
Committee and consistent with the NIH Guide for the Care and Use of
Laboratory Animals.
Study drug: AC3174 ([Leu14]exendin-4) is an exenatide analog with a
single amino-acid substitution, leucine for methionine at position 14, done
to eliminate the potential oxidation at methionine and potentially improve
shelf-life stability.19 AC3174 binds to the GLP-1R in vitro and shares many
of the biological and glucoregulatory activities of exenatide and GLP-1
in vivo. For additional details on the pharmacological proﬁle of the
compound, see Hargrove et al.19 For this study, four doses of AC3174 were
examined, that is, 0, 0.03, 0.10 and 0.30 μg kg− 1.
Study design: The general study design for the model of alcohol
dependence and relapse drinking was similar to that previously
Table 2. Sample characteristics for the SAGE study
Alcohol dependent Controlsa
Total Women Men Total Women Men
N (%) 1917 (100) 746 (38.9) 1171 (61.1) 1886 (100) 1299 (68.9) 587 (31.1)
Age (s.d.) 39.0 (9.3) 37.9 (8.3) 39.7 (9.8) 39.3 (9.1) 39.4 (8.8) 39.2 (9.9)
Self-reported ancestry
Caucasian 1244 (64.9) 483 (64.7) 761 (65.0) 1391 (73.5) 975 (74.8) 416 (70.6)
African American 671 (35.0) 261 (35.0) 410 (35.0) 495 (26.1) 324 (24.8) 171 (29.0)
Self-reported ethnicity
Hispanics 78 (4.1) 21 (2.8) 57 (4.9) 60 (3.2) 38 (2.9) 22 (3.7)
Nicotine dependence 1311 (68.4) 548 (73.5) 763 (65.2) 369 (19.5) 292 (22.4) 77 (13.1)
Abbreviation: SAGE, Study of Addiction: Genetics and Environment. aNot including controls who endorsed ⩾ 3 DSM-IV symptoms of alcohol dependence, but
did not cluster within a 12-month period (N= 55). Data are presented as N (%) unless otherwise speciﬁed.
Table 3. Sample characteristics for the IV-ASA study
Total sample Women Men
N (%) 84 (100) 47 (56.0) 37 (44.0)
Age (s.d.) 25.5 (4.2) 25.6 (4.2) 25.2 (4.3)
Self-reported ancestry
Caucasian 72 (85.7) 39 (83.0) 33 (89.2)
African American 12 (14.3) 8 (17.0) 4 (10.8)
Self-reported Ethnicity
Hispanics 4 (4.8) 2 (4.3) 2 (5.4)
Smokersa 5 (6.9) 4 (10.3) 1 (3.0)
Current alcohol
dependence
0 0 0
Past alcohol dependence 0 0 0
Current alcohol abuse 0 0 0
Past alcohol abuse 5 (6.0) 5 (10.6) 0
Lifetime psychiatric comorbidityb
Mood disorder 5 (2.9) 4 (8.7) 1 (2.7)
Anxiety disorder 4 (5.8) 2 (5.4) 2 (6.3)
Substance use disorderc 0 0 0
Eating disorder 0 0 0
Abbreviation: IV-ASA, intravenous alcohol self-administration. aSmoking
status reported by 72 subjects. bComplete Structured Clinical Interview for
DSM-IV-TR Axis I Disorders (SCID) available for 83 subjects. cNot including
alcohol use disorder. Data are presented as N (%) unless otherwise
speciﬁed.
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reported.20,21 Brieﬂy, mice were ﬁrst trained to drink alcohol (15% v/v) in a
two-bottle choice (water as the alternative ﬂuid) limited access (2 h
per day) procedure. Voluntary drinking sessions started 30min before the
start of the dark phase of the circadian cycle. Once stable baseline drinking
was established, mice were separated into two groups. One group (EtOH
group) received repeated weekly cycles of chronic intermittent exposure
(16 h per day for 4 days) to alcohol vapor in inhalation chambers. The
remaining mice (CTL group) were similarly treated, but maintained in
control (air) inhalation chambers. After a 72 h forced-abstinence period
following each weekly inhalation exposure cycle, EtOH and CTL mice were
given the opportunity to voluntarily drink alcohol under the same limited
access conditions as baseline for ﬁve consecutive days. Thus, as depicted in
Supplementary Figure S2, each weekly chronic intermittent alcohol (or air)
exposure cycle was followed by a 5-day limited access drinking test cycle,
and this pattern of treatment was repeated for several cycles. During
baseline and test cycles 1–4 drinking sessions, all the mice received
intraperitoneal injections of vehicle (saline) 15 min before access to alcohol
to habituate them to this manipulation. During test cycles 5, 6 and 7, EtOH
and CTL mice were further divided (N= 9–10 per group) to receive
intraperitoneal injections of saline or AC3174 (0.03, 0.10, 0.30 μg kg− 1)
15min before limited access drinking test sessions. Finally, mice received
an additional two exposure cycles and during test cycles 8 and 9, all the
mice were injected with vehicle before each drinking session. These
testing periods served as a drug washout evaluation to test for any long-
lasting effect of treatment on voluntary alcohol intake (see Supplementary
Figure S2).
Statistical analyses
LCTS study (Study 1). For the case–control study, association between
genotype and affection status were calculated using logistic regression
controlling for ancestry (self-reported) and determined by the odds ratio
and the corresponding 95% conﬁdence interval. An additive model was
assumed, coding the genotype as 0, 1 or 2 depending on the number of
minor alleles that were present. The odds ratio thus represents the odds for
AUD associated with each copy of the minor allele. To adjust for multiple
testing, the MeffLi (effective number of independent marker loci) method,
a correction method taking into account the correlation between the
studied SNPs, was applied using the online software SNPSpD (available at
http://gump.qimr.edu.au/general/daleN/SNPSpD).22,23 Separate logistic
regression analyses were also carried out within self-reported ancestral
categories. Haplotype-based analyses were also conducted for Study 1 and
2 (see Supplementary Information).
Nicotine dependence and AUD are highly comorbid,24 and smoking-
related variables correlate with alcohol dependence severity.25 We,
therefore, carried out post hoc analyses to evaluate the association of
the GLP1R markers with smoking status. For this analysis, participants were
divided into three groups: non-smoking controls, non-smoking subjects
with AUD and smoking subjects with AUD. Few control subjects were
smokers and this group was thus excluded from the analysis. Comparisons
between allele frequencies in the three groups were investigated in self-
reported Caucasians and African Americans separately using χ2 test and
Cochran–Armitage trend test.
SAGE study (Study 2). SNPs nominally associated with AUD in the LCTS
study were tested for association with alcohol dependence in the whole
SAGE sample as well as in males and females separately by logistic
regression controlling for ancestry using principal component factors, PC1
and PC2, with PC1 distinguishing between European and African ancestry
and PC2 distinguishing between Hispanic and non-Hispanic subjects.
IV-ASA study (Study 3). We carried out post hoc analyses of the human
laboratory data to examine whether risk alleles identiﬁed in the case–
control study were also associated with measures of alcohol self-
administration in the IV-ASA experiment: peak BrAC, average BrAC, total
number of rewards, total alcohol self-administered in grams and number
of subjects reaching a BrAC of 80mg% (corresponding to a binge
exposure). Outcomes were analyzed using linear or logistic regression
models, controlling for age, body mass index, gender and ancestry, with
genotype evaluated using an additive model (coded as 0, 1 or 2 depending
on the number of minor alleles).
Statistical analyses for studies 1–3 were carried out using IBM SPSS
statistics for Windows (version 20.0.0, IBM, Armonk, NY, USA) and PLINK.13
fMRI study (Study 4). The fMRI analyses were carried using the Analysis of
Functional NeuroImages software.26 The three fMRI runs were concate-
nated, time shifted, motion corrected, warped into Talairach space as
3.5 mm isotropic voxels and smoothed to a full width at half maximum of
6mm. Processed time series for each subject were then modeled with
canonical hemodynamic responses time-locked to anticipatory cues of
high reward, low reward and neutral conditions with the respective trial
outcome notiﬁcations (feedback); in addition, head motion parameters
were also entered into the model as regressor of no interest. The following
linear contrasts were generated and used for group analysis: cue of high
($10)/low ($1) reward, cue of high/low reward vs neutral ($0), the
respective feedbacks alone and vs the neutral feedback condition.
Canonical hemodynamic responses and time-series data sets were scaled
so that beta weights could be interpreted as percent-signal-change. A
voxel-wise, between-group comparison for the entire brain was carried out
using Multivariate Modeling (3dMVM),27 with one contrast per condition
and per subject, including subject’s self-reported ancestry as a categorical
factor. Results were corrected for multiple comparison at a small volume of
interest using the 3dClustSim program in Analysis of Functional
NeuroImages (v.2011) by generating 1000 Monte Carlo simulations on a
volume 8918mm3, centered in the activated cluster, using 8mm full width
at half maximum of smoothing and voxel size of 3.5 × 3.5 × 3.5 mm3 to
determine the cluster size at which the false positive probability was below
a desired alpha level of Pcorro0.05. Average percent BOLD signal change
(region of interest (ROI) analysis) was obtained from the beta weights
generated for each task condition for a small spherical volume (8 mm
diameter) centered at the peak-activated voxel of the signiﬁcant clusters
(right globus pallidus) as well as the left globus pallidus, left and right
nucleus accumbens and ventral tegmental area and then analyzed using t-
test.
GLP-1R agonism in a mouse model of alcohol dependence (Study
5). Preliminary analyses of the data indicated that there were no
signiﬁcant variations in alcohol intake across days during each test cycle.
Therefore, alcohol intake data (g kg− 1) were averaged over 5 days of
testing and analyzed by factorial analysis of variance (ANOVA) with group
(EtOH vs CTL) and treatment (0, 0.03, 0.10, 0.30 μg kg− 1 AC3174) as main
factors for each testing period.
RESULTS
LCTS study (Study 1)
Single marker associations. The 26 SNPs for the whole case–
control sample (that is, both Caucasian and African American
subjects) were submitted to SNPSpD and gave a MeffLi of 16.0 and
a signiﬁcance threshold of Po0.0032. Signiﬁcant associations
with affection status were observed for four SNPs (Table 4). Post
hoc analysis was performed to investigate whether these results
were replicable across ancestral groups. Despite large differences
in allele frequencies (Supplementary Table S2) and a greatly
underpowered African American sample, replications (rs7766663,
rs2235868 and rs7769547) or a trend-level replication
(rs10305512) were found for all four SNPs in both ancestral
groups (Table 4). See Supplementary Information for further
results on single maker and haplotype analyses.
Post hoc analyses. We conducted post hoc analyses with the four
associated SNPs and the two functional SNPs included in the
haplotype block (see Supplementary Information). Comparing
allele frequencies among non-smoking controls, non-smoking
AUD and smoking AUD subjects using a χ2 test revealed that the
non-smoking AUD group formed an intermediate group with the
highest risk allele frequencies in the smoking AUD group
(Figure 1). This was replicated across the two ancestral groups
and seen for three of the six SNPs (Caucasians: rs2235868
P= 0.030, rs7769547 P= 0.026, rs10305512 Po0.001; African-
Americans: rs2235868 P= 0.0043, rs7769547 Po0.001,
rs10305512 P= 0.012). In addition, the results of the χ2 analyses
suggested linear trends in allele frequencies across the three
groups. Consequently, we applied the Cochran–Armitage test and
found that the results remained signiﬁcant for all SNPs, with P-
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values even smaller than those reported for the χ2 analyses.
To investigate whether non-smoking AUD and smoking AUD
subjects differed in AUD severity, we performed a linear regression
using group as the independent factor, and, as the dependent
factor, we used number of heavy drinking days (deﬁned as ⩾ 4/5
drinks per day for women/men) during a 90-day-period as
reported in the timeline follow-back self-report questionnaire,28
controlling for age and gender. We found signiﬁcantly more heavy
drinking days in the smoking AUD subjects (F(3,568) = 13.5,
B= 11.6, Po0.001).
SAGE study (Study 2)
None of the SNPs nominally associated with AUD in the LCTS
study were associated with affection status in SAGE when the
whole sample was investigated. However, when the sample was
split by gender, a logistic regression controlling for PC1 and PC2
showed that the 168Ser/Ser genotype was associated with alcohol
dependence in males (β= 0.190, s.e. = 0.089, N= 1752, P= 0.033)
but not in females (β=− 0.072, s.e. = 0.078, N= 2036, P= 0.357). On
the basis of these results, we reanalyzed the LCTS case–control
results for the relevant SNPs splitting the sample by gender and
found the same pattern with a more pronounced association in
males (Supplementary Table S3). However, we also observed that
association between rs7769547 and AUD in the LCTS sample was
replicated in both genders, and there was a trend toward
replication for three of the SNPs (rs7766663, rs2235868 and
rs10305512). See Supplementary Information for further results
involving haplotype analyses.
IV-ASA study (Study 3)
Data from the IV-ASA study were analyzed against the SNPs
nominally associated with AUD in Study 1. Signiﬁcant associations
were seen for rs6923761 with average BrAC, peak BrAC and the
percent of subjects that reached a BrAC of 80 mg% (Table 5). Each
of these measures was shown to increase with the addition of
each 168Ser allele.
fMRI study (Study 4)
On the basis of the results from Studies 1–3, the sample for
Study 4 was divided according to rs6923761 genotype in which
168Ser (A) allele carriers were merged into one group: group
168Ser/Gly+168Ser/Ser (ﬁve males, ﬁve females; age: 31.5 ± 6.3;
ancestry: seven Caucasians, two African Americans and one
unknown); and group 168Gly/Gly(six males, six females; age:
32.7 ± 6.5; ancestry: seven Caucasians, four African American and
one multiethnic ancestry). The groups did not differ for either
gender or age.
There was a signiﬁcant difference (Pcorro0.05) in brain
activation within the right globus pallidus when contrasting the
genotypes (168Gly/Gly) vs (168Ser/Gly+168Ser/Ser) for the
rs6923761 SNP. Those carrying the non-risk allele (that is,
168Gly/Gly group) had lower BOLD response than those carrying
the risk allele (168Ser/Gly+168Ser/Ser group) when receiving
notiﬁcation of outcome (feedback) for high reward (peak T=− 4.8).
A similar group difference was observed for the contrasted task
condition: notiﬁcation of outcome of high reward vs low reward
(peak T=− 3.4). We then computed the mean percent signal
change of ROIs as described above to further verify these ﬁndings.
The only signiﬁcant difference was found from the ROI located on
right globus pallidus for high reward between group contrast
(Figure 2). No signiﬁcant group difference was observed for other
task conditions (contrasts) or other brain areas under the same
contrast.
Table 4. Genetic association testing between GLP1R SNPs and alcohol use disorder
GLP1R SNP Minor allele/major allele Caucasian and African American Caucasian African American
N OR (95% CI) P-valuea N OR (95% CI) P-valueb N OR (95% CI) P-valueb
rs7738586 A/C 904 0.76 (0.54–1.05) 0.0983 602 0.76 (0.51–1.12) 0.1597 302 0.75 (0.39–1.44) 0.3836
rs9296274 G/A 904 0.81 (0.60–1.09) 0.1678 602 0.88 (0.60–1.30) 0.5211 302 0.71 (0.45–1.14) 0.1601
rs2268657 C/T 901 0.98 (0.78–1.22) 0.8429 600 1.00 (0.78–1.29) 0.9969 301 0.91 (0.58–1.43) 0.6871
rs3799707 T/G 902 1.07 (0.84–1.38) 0.5753 601 1.03 (0.79–1.35) 0.8081 301 1.34 (0.69–2.60) 0.3917
rs10305439 A/C 903 1.13 (0.90–1.43) 0.2910 603 1.10 (0.86–1.42) 0.4442 300 1.29 (0.72–2.32) 0.3881
rs2143734 G/A 903 0.79 (0.63–0.99) 0.0412 602 0.82 (0.63–1.07) 0.1539 301 0.68 (0.43–1.09) 0.1078
rs2268650 A/G 902 1.31 (1.02–1.68) 0.0345 600 1.28 (0.98–1.67) 0.0666 302 1.55 (0.72–3.33) 0.2664
rs910170 A/G 904 0.85 (0.69–1.06) 0.1443 603 0.89 (0.69–1.13) 0.3359 301 0.76 (0.50–1.17) 0.2116
rs874900 G/A 850 0.76 (0.53–1.07) 0.1161 561 0.53 (0.32–0.88) 0.0146 289 1.03 (0.63–1.67) 0.9148
rs6923761 A/G 904 1.46 (1.12–1.89) 0.0047 602 1.45 (1.10–1.90) 0.0083 302 1.54 (0.67–3.59) 0.3119
rs7766663 T/G 842 1.42 (1.13–1.79) 0.0032 565 1.32 (1.02–1.72) 0.0365 277 1.90 (1.11–3.28) 0.0202
rs7341356 G/A 847 1.43 (1.12–1.81) 0.0035 568 1.35 (1.03–1.77) 0.0296 279 1.72 (1.03–2.86) 0.0379
rs2235868 C/A 904 1.49 (1.18–1.87) 0.0006 602 1.43 (1.10–1.86) 0.0070 302 1.70 (1.05–2.74) 0.0311
rs1042044 A/C 904 0.81 (0.65–1.00) 0.0512 604 0.84 (0.65–1.07) 0.1617 300 0.73 (0.48–1.11) 0.1448
rs932443 C/T 902 0.78 (0.62–0.98) 0.0313 601 0.81 (0.62–1.05) 0.1168 301 0.71 (0.46–1.09) 0.1187
rs12204668 C/T 901 0.81 (0.64–1.02) 0.0678 601 0.82 (0.64–1.07) 0.1399 300 0.74 (0.43–1.25) 0.2586
rs1076733 A/G 901 1.18 (0.95–1.47) 0.1316 600 1.15 (0.89–1.48) 0.2836 301 1.28 (0.84–1.95) 0.2521
rs7769547 A/G 904 0.70 (0.56–0.87) 0.0013 603 0.75 (0.58–0.97) 0.0304 301 0.58 (0.38–0.88) 0.0102
rs2300613 A/G 902 0.72 (0.57–0.91) 0.0068 602 0.70 (0.53–0.92) 0.0104 300 0.79 (0.48–1.28) 0.3397
rs2268640 G/A 905 1.03 (0.83–1.30) 0.7665 603 0.98 (0.77–1.25) 0.8631 302 1.48 (0.78–2.82) 0.2324
rs2206942 T/C 905 0.91 (0.73–1.12) 0.3689 603 0.88 (0.69–1.13) 0.3084 302 1.00 (0.63–1.58) 0.9988
rs10305512 A/G 902 0.53 (0.37–0.76) 0.0006 602 0.37 (0.20–0.66) 0.0009 300 0.66 (0.42–1.05) 0.0787
rs10305514 T/G 906 0.93 (0.62–1.39) 0.7230 604 0.85 (0.51–1.43) 0.5365 302 1.07 (0.55–2.05) 0.8462
rs4714210 G/A 902 1.03 (0.82–1.29) 0.8197 601 1.06 (0.83–1.36) 0.6400 301 0.89 (0.54–1.48) 0.6586
rs4254984 C/T 903 0.98 (0.78–1.23) 0.8632 602 1.03 (0.80–1.32) 0.8420 301 0.80 (0.47–1.35) 0.4026
rs9968886 A/G 906 0.87 (0.67–1.14) 0.3187 604 0.85 (0.60–1.21) 0.3628 302 0.90 (0.60–1.37) 0.6369
Abbreviations: CI, conﬁdence interval; GLP1R; glucagon-like peptide-1 receptor; OR, odds ratio; SNP, single-nucleotide polymorphism. aLogistic regression
controlling for ancestry; the effective number of independent marker loci (MeffLi) correction was used with a cut-off P-value of 0.0032. SNPs meeting this cut-
off in the whole sample are in bold. bPost hoc analysis using logistic regression; P-values were not adjusted.
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GLP-1R agonism in a mouse model of alcohol dependence
(Study 5)
Consistent with previously published work,20,21 EtOH mice showed
signiﬁcant progressive escalation of voluntary alcohol intake over
their baseline intake, compared with CTL mice, whose intake
remained relatively stable over successive four exposure/test
cycles. Intake data during the last test cycle before AC3174
treatment indicated a signiﬁcant difference between EtOH and
CTL mice (F(1,67) = 13.61, Po0.0001). Analysis indicated that EtOH
mice consumed signiﬁcantly more alcohol than CTL mice, and this
effect did not differ at baseline (that is, before drug administra-
tion) across the different treatment groups (F(3,67)o1.0; P, not
signiﬁcant). Results indicate that AC3174 signiﬁcantly reduced
alcohol consumption in a mouse model of alcohol dependence
(Figures 3a–e).
AC3174 treatment #1 (alcohol intake during test cycle 5). EtOH
mice consumed signiﬁcantly more alcohol than CTL mice (main
effect of group (F(1,67) = 31.80, Po0.001)). However, ANOVA
failed to indicate a main effect of treatment or group × treatment
interaction (Figure 3a).
AC3174 treatment #2 (alcohol intake during test cycle 6). There
was a signiﬁcant main effect of group (F(1,67) = 27.88, Po0.001),
with EtOH mice consuming a greater amount of alcohol than CTL
mice. Again, ANOVA failed to indicate a main effect of treatment
or group × treatment interaction (Figure 3b).
AC3174 treatment #3 (alcohol intake during test cycle 7). ANOVA
indicated a signiﬁcant main effect of group (F(1,65) = 31.44,
Po0.00001) and a signiﬁcant group × treatment interaction (F
(3,65) = 4.01, Po0.025). Post hoc comparisons (Newman–Keuls
test) indicated that, as expected, EtOH mice injected with vehicle
consumed more alcohol than CTL mice. In addition, all doses of
AC3174 signiﬁcantly reduced drinking compared with the vehicle
condition in EtOH mice, while AC3174 treatment did not
signiﬁcantly alter alcohol intake in nondependent CTL mice.
Further, AC3174 treatment abolished the difference in alcohol
intake between EtOH and CTL conditions (Figure 3c).
Figure 1. Comparison of risk allele frequencies between non-smoking controls, non-smoking subjects with alcohol use disorder (AUD) and
smoking subjects with AUD in the LCTS study using Pearson χ2 test. Total n for the three groups were 125–130, 121–128, 202–215 for the
Caucasian sample and 26–29, 47–50, 137–147 for the African American sample, respectively. *Po0.05, **Po0.01, ***Po0.005. LCTS,
Laboratory of Clinical and Translational Studies.
Table 5. Measures from the IV-ASA experiment sorted by the rs6923761 genotype
168Gly/Gly (N= 49) 168Ser/Gly (N= 26) 168Ser/Ser (N= 5) β/OR P-value
Average BrAC (mg%) 34.39 (±28.99) 40.57 (±26.71) 57.26 (±31.49) 8.874 0.048
Peak BrAC (mg%) 53.37 (±37.26) 65.72 (±38.49) 83.59 (±40.33) 13.864 0.026
Number of button presses ad lib 11.39 (±7.85) 11.85 (±7.64) 15.60 (±8.85) 1.195 0.211
Total alcohol infused 33.02 (±23.50) 40.11 (±25.05) 47.11 (±25.05) 6.771 0.052
Binge ⩾ 80mg%: yes (%)a 18 (36.73) 13 (50.00) 4 (80.00) 2.159 0.037b
Abbreviations: BrAC, breath alcohol concentration; OR, odds ratio. aData are presented as number of subjects reaching a BrAC of 80mg% signifying a binge session.
bP-values are one-tailed and obtained by logistic regression and an additive genetic model. All analyses were controlled for age, body mass index, gender and
ancestry. All data are presented as mean (s.d.) unless speciﬁed otherwise. P-values are one-tailed and obtained by linear regression unless speciﬁed otherwise.
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Placebo (washout) test #1 (alcohol intake during test cycle 8). All
mice were treated with saline (drug-washout test) to substantiate
the apparent efﬁcacy of AC3174 to reduce escalated alcohol
drinking in dependent mice. ANOVA revealed a signiﬁcant main
effect of Group (F(1,64) = 38.61, Po0.00001) and a signiﬁcant
group × treatment interaction (F(3,64) = 4.14, Po0.01). Post hoc
comparisons supported the expected greater alcohol intake in
EtOH compared with CTL mice that continued to receive vehicle. A
similar proﬁle of results was obtained in mice that received the
lowest AC3174 dose (0.03 μg kg− 1) in the previous test cycle.
However, EtOH mice that received 0.10 or 0.30 μg kg− 1 AC3174
doses in the previous test period continued to consume
signiﬁcantly less alcohol compared with mice that previously
received vehicle, and their lower level of intake was similar to that
exhibited by the corresponding CTL groups (Figure 3d).
Placebo (washout) test #2 (alcohol intake during test cycle
9). ANOVA indicated a signiﬁcant main effect of group (F
(1,64) = 16.30, Po0.001), but no effect of treatment or an
interaction between group× treatment during this second wash-
out test period. These results indicate that after a second week of
placebo (saline) treatment, elevated drinking in EtOH compared
with CTL mice was restored in all the test groups (Figure 3e).
DISCUSSION
We report a set of studies which, taken together, support the
hypothesis that GLP-1R has a role in AUD and represents a novel
therapeutic target. First, we report evidence and replication that
genetic variation in GLP1R is associated with AUD and alcohol
dependence in humans. In addition to providing an internal
replication by splitting the LCTS sample by ancestry, we conﬁrmed
the nominal association between AUD and rs6923761 in this
sample by showing a similar association with alcohol dependence
in males from an independent cohort (SAGE). Albeit exploratory in
its nature, preliminary human functional validation was obtained
from two studies, in which the GLP1R 168Ser allele was associated
with increased measures of alcohol self-administration from the
IV-ASA study, and signiﬁcantly higher BOLD signal in an fMRI study
at the globus pallidus when participants received rewarding
feedback during the Monetary Incentive Delay task. Finally, we
report that pharmacological GLP-1R agonism with AC3174
signiﬁcantly reduced alcohol consumption in a mouse model of
alcohol dependence.
GLP-1 inﬂuences appetite and reward function through
peripheral and central actions on the GLP-1R.29 It decreases food
intake in both humans and animals,30 a mechanism most likely to
involve GLP-1R activation in the area postrema, central nucleus of
the amygdala and nucleus of the solitary tract.31,32 GLP-1Rs are
also present in areas involved with reward processing such as
globus pallidus, ventral tegmental area and nucleus accumbens.
The nucleus of the solitary tract contains GLP-1-producing
neurons,1 which project directly to the ventral tegmental area
and nucleus accumbens.5 The nucleus of the solitary tract also
receives vagal afferents from the stomach providing an additional
mechanism through which peripherally secreted GLP-1 signals the
brain.1
An in vitro study reported the effect on receptor function by one
of the SNPs nominally associated with AUD in this study. Using
cells expressing wild-type and polymorphic human GLP1R, the
168Ser (A-allele) was associated with decreased GLP-1R cell
surface expression compared with their complementary alleles.33
Although the afﬁnity for a range of GLP-1 agonists was unaffected
by genotype, the efﬁcacy of agonist response was lower for the
Figure 2. Statistical maps for fMRI analysis contrasting the genotype groups 168Gly/Gly × 168Ser/Gly+168Ser/Ser in the rs6923761 SNP.
Statistical maps (top) and ROI results (bottom) for notiﬁcation of high reward (left) and its net difference with low reward (right) contrasting
(168Gly/Gly)− (168Ser/Gly+168Ser/Ser) are shown; ROI localization is displayed in yellow at the axial view in the bottom. fMRI, functional
magnetic resonance imaging; SNP, single-nucleotide polymorphism.
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168Ser variant, presumably because of its lower expression.33
Seemingly in agreement with the in vitro ﬁndings, the 168Ser
allele was associated with lower insulin response following GLP-1
infusion in healthy volunteers34 and with lower metabolic/
cardiovascular biomarkers in obese females.35 Furthermore, a
haplotype uniquely including the 168Ser allele was associated
with signiﬁcantly better response to perphenazine and worse
response to olanzapine, providing support for potential pharma-
cogenetic interactions.36 In addition, the 260Phe allele (C) of
Phe260Leu (rs1042044), which here was associated with AUD at a
trend level, has previously been associated with signiﬁcantly
higher morning salivary cortisol levels in children compared with
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Figure 3. GLP-1R agonism in a mouse model of alcohol dependence. (a) AC3174 treatment #1 (alcohol intake during test cycle 5): EtOH mice
consumed signiﬁcantly more alcohol than CTL mice (Po 0.001). Analysis of variance (ANOVA) failed to indicate a main effect of treatment or
group× treatment interaction. (b) AC3174 treatment #2 (alcohol intake during test cycle 6): there was a signiﬁcant main effect of group
(Po0.001), with EtOH mice consuming a greater amount of alcohol than CTL mice. ANOVA failed to indicate a main effect of treatment or
group× treatment interaction. (c) AC3174 treatment #3 (alcohol intake during test cycle 7): ANOVA indicated a signiﬁcant main effect of group
(Po0.00001) and a signiﬁcant group × treatment interaction (Po0.025). Post hoc comparisons indicated that, as expected, EtOH mice injected
with vehicle consumed more alcohol than CTL mice. In addition, all doses of AC3174 signiﬁcantly reduced drinking compared with the vehicle
condition in EtOH mice, while AC3174 treatment did not signiﬁcantly alter alcohol intake in nondependent CTL mice. Further, AC3174
treatment abolished the difference in alcohol intake between EtOH and CTL conditions. (d) Placebo (washout) test #1 (alcohol intake during
test cycle 8): all mice were treated with saline (drug-washout test) to substantiate the apparent efﬁcacy of AC3174 to reduce escalated alcohol
drinking in dependent mice. ANOVA revealed a signiﬁcant main effect of group (Po0.00001) and a signiﬁcant group× treatment interaction
(Po0.01). Post hoc comparisons supported the expected greater alcohol intake in EtOH compared with CTL mice that continued to receive
vehicle. A similar proﬁle of results was obtained in mice that received the lowest AC3174 dose (0.03 μg kg− 1) in the previous test cycle.
However, EtOH mice that received 0.10 or 0.30 μg kg− 1 AC3174 doses in the previous test period continued to consume signiﬁcantly less
alcohol compared with mice that previously received vehicle, and their lower level of intake was similar to that exhibited by the
corresponding CTL groups. (e) Placebo (washout) test #2 (alcohol intake during test cycle 9): ANOVA indicated a signiﬁcant main effect of
group (Po0.001), but no effect of treatment or an interaction between group× treatment during this second washout test period. These
results indicate that after a second week of placebo (saline) treatment, elevated drinking in EtOH compared with CTL mice was restored in all
the test groups. *Po0.05, signiﬁcantly different from corresponding CTL group; ^Po0.05, signiﬁcantly different from corresponding
vehicle group.
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homozygotes for the 260Leu allele.37 This is consistent with the
previously reported role of GLP-1 signaling in activating the
hypothalamic–pituitary–adrenal axis, which in turn is important
for the etiology of AUD.38
The gender differences reported here, with the rs6923761 being
associated with alcohol dependence only in males of the SAGE
cohort, ﬁnd support in the literature. The prevalence of AUD is
higher among men than women and twin pair correlations for
AUD has been reported to be lower in opposite-sex dizygotic
twins when compared with same-sex dizygotic twins.39 One of
several possible explanations for the differences in genetic sources
of liability is the fact that, while men and women share the same
AUD susceptibility genes, there may still be sex differences in
genetic background and/or gene–gene interaction.39 However, it
is worth noting that a secondary analysis in the LCTS sample
revealed further replications and trend-level replications across
genders for some of the associated SNPs.
There is one main difference between the SAGE and the LCTS
cohorts. In SAGE, all cases were alcohol dependent, and although
cases in the LCTS cohort were mainly alcohol-dependent subjects,
we also included alcohol abusers (N= 59). Alcohol abuse and
dependence, the two syndromes included in the AUD diagnosis,
have a shared etiology,40 which is consistent with the fact that we
were able to replicate our ﬁndings from LCTS in the male sample
of SAGE.
The association between GLP1R risk alleles and AUD was most
pronounced in individuals who were also smokers, a ﬁnding
replicated across the two ancestral groups. Alcohol and nicotine
addiction are frequently comorbid and have overlapping genetic
vulnerability41 and neurobiological factors. Nicotine use among
AUD subjects is also associated with a greater severity of alcohol
dependence.25 This is consistent with our results, not only as the
smoking AUD subjects had signiﬁcantly more heavy drinking days
than non-smoking AUD subjects, but we also found a graded
increase in risk allele frequencies when comparing non-smoking
control, non-smoking AUD and smoking AUD subjects. Notably, a
preclinical study showed that GLP-1R agonism attenuates
nicotine-induced effects.42 These ﬁndings hold potentially impor-
tant clinical implications because alcoholic smokers have an
increased risk of tobacco-related mortality and morbidity.43
Given the possible functional role of SNPs discussed above,
coupled to the ﬁndings reported here, we hypothesize that
variations in GLP1R may affect GLP-1 expression and signaling
both peripherally and centrally. This, in turn, may moderate
responses to alcohol, and/or motivation to consume it. As human
genetic association studies are fraught with numerous potential
confounds, we validated our ﬁndings using two human experi-
mental paradigms conducted in rigorous and well-controlled
conditions. As a ﬁrst step toward functional validation in humans,
we found that with increased number of the GLP1R 168Ser alleles,
subjects self-administered alcohol to a higher level as indicated by
increased average and peak BrAC and increased number of
subjects reaching a BrAC of 80 mg%. This observation provides an
intriguing, albeit preliminary, indication that the 168Ser GLP1R
variant inﬂuences alcohol-drinking behavior, which in turn may
predispose towards AUD as seen in the case–control analyses. We
can only speculate on the mechanism underlying this relationship;
however, given the previous in vitro functional report for the
168Ser allele,33 we postulate that decreased function of the SNP
attenuates the regulatory properties of GLP-1R, including alcohol
intake as demonstrated in preclinical studies,6,7 (present Study 5)
leading to alcohol self-administration and increased susceptibility
for AUD. As a second step toward functional validation in humans,
we found that alcohol-dependent individuals carrying the 168Ser
allele had signiﬁcantly higher BOLD signal than the homozygote
group carrying the complementary allele at the globus pallidus
when receiving notiﬁcation of reward. Human neuroimaging
studies have shown that the globus pallidus is related to reward
processing,44,45 which is consistent with preclinical studies
indicating its involvement in reward via ventral striatal dopami-
nergic projections to the globus pallidus.46 Given the positive
correlation between reward-related mesolimbic activations and
striatal dopamine release,47 these fMRI results, though preliminary,
suggest that those carrying the risk allele may have a more
dysfunctional reward system that contributes to their higher
vulnerability to AUD. Notably, the globus pallidus has a high
concentration of GLP-1 binding sites in the human brain.3
Although speculative, these preliminary data are consistent with
recent work suggesting that activation of GLP-1R modulates
dopamine signaling,6,48,49 which in turn is dysregulated in AUD.50
Given the emerging importance of epigenetic modiﬁcation in
addictions,51 future research will also need to investigate the
possible role of epigenetic mechanisms in regulating the GLP-1R
gene in AUD.
The GLP-1R agonist, exendin-4, has previously been shown to
reduce alcohol intake, alcohol-induced reward and the motivation
to consume alcohol in rodents,6,7 whereas the GLP-1R antagonist,
exendin-9-39, increased alcohol intake in rats.7 Our a priori
hypothesis was that the receptor rather than the peptide itself
has a key role in alcohol-related seeking behaviors. Therefore, our
human analyses were a priori limited to the gene encoding the
receptor. Consistent with our hypothesis and the results obtained
in these human experiments, we found converging evidence in a
mouse model of alcohol dependence where pharmacological
GLP-1R agonism via an exendin-4 analog (AC3174) signiﬁcantly
reduced alcohol consumption. Interestingly, in nondependent
mice, AC3174 did not affect modest levels of voluntary alcohol
consumption, nor was it effective in reducing elevated alcohol
drinking in dependent mice during its ﬁrst administration.
However, with extended administration (over additional test
cycles), AC3174 was effective in selectively reducing escalated
drinking exhibited by dependent mice. This effect, once estab-
lished, was relatively long lasting in mice receiving the higher
doses. Only after a second washout test cycle did alcohol
consumption in dependent mice return to pre-treatment alcohol
intake levels, thus suggesting that the effects of AC3174 may
manifest after chronic treatment.
Our reverse translation (Study 5) of the human work was
conducted via a pharmacological probe rather than a knockout
genetic model. This approach is more clinically relevant and
therefore strengthens this set of studies. However, future studies
are needed to fully understand the properties of AC3174 itself as a
potential treatment for AUD, including locomotor activity, loss of
righting reﬂex, pharmacokinetics/pharmacodynamics and operant
procedure studies, as well as experiments addressing its speciﬁcity
for alcohol intake (for example, compared with saccharine or
sucrose intake, as well as control measures such as water and food
intake). Though future studies will need to address these
limitations, it is important to point out that the current preclinical
study is in line with previous experiments in rodents,6,7 which
incidentally reported no effect of the GLP-1 analog exendin-4 on
such control measures. The current study further adds novel
important information, that is, (1) it provides evidence from a
different animal model and lab; (2) it holds signiﬁcant clinical
relevance, given that the effects were speciﬁcally detected in a
mouse model of alcohol dependence; and (3) it was not
conducted with exendin-4 itself but rather with another analog,
thus providing additional evidence toward our overall hypothesis
on the speciﬁc role of the GLP-1R regardless of its ligand (for
example, GLP-1, exendin-4 or AC3174) in excessive alcohol
consumption.
There is a large need for effective pharmacotherapies for AUD
that can be tailored to individual risk factors and/or also provide a
biologically oriented treatment integrated with individualized
psychotherapies.38 Notably, GLP-1 analogs are already approved
and clinically used for the treatment of type 2 diabetes. Our study
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suggests the GLP-1R as a candidate treatment target, potentially
with a particular utility in a genetically identiﬁed subpopulation of
AUD patients.
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